Literature DB >> 15781327

Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.

P Cuniasse1, L Devel, A Makaritis, F Beau, D Georgiadis, M Matziari, A Yiotakis, V Dive.   

Abstract

Despite a deep knowledge on the 3D-structure of several catalytic domains of MMPs, the development of highly specific synthetic active-site-directed inhibitors of MMPs, able to differentiate the different members of this protease family, remains a strong challenge. Due to the flexible nature of MMP active-site, the development of specific MMP inhibitors will need to combine sophisticated theoretical and experimental approaches to decipher in each MMP the specific structural and dynamic features that can be exploited to obtain the desired selectivity.

Mesh:

Substances:

Year:  2005        PMID: 15781327     DOI: 10.1016/j.biochi.2004.09.025

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  36 in total

1.  Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

Authors:  Janelle Lauer-Fields; Keith Brew; John K Whitehead; Shunzi Li; Robert P Hammer; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-08-02       Impact factor: 15.419

Review 2.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

3.  Screening of the binding of small molecules to proteins by desorption electrospray ionization mass spectrometry combined with protein microarray.

Authors:  Chenxi Yao; Tao Wang; Buqing Zhang; Dacheng He; Na Na; Jin Ouyang
Journal:  J Am Soc Mass Spectrom       Date:  2015-07-15       Impact factor: 3.109

4.  Allosteric inhibition of the neuropeptidase neurolysin.

Authors:  Christina S Hines; Kallol Ray; Jack J Schmidt; Fei Xiong; Rolf W Feenstra; Mia Pras-Raves; Jan Peter de Moes; Jos H M Lange; Manana Melikishvili; Michael G Fried; Paul Mortenson; Michael Charlton; Yogendra Patel; Stephen M Courtney; Chris G Kruse; David W Rodgers
Journal:  J Biol Chem       Date:  2014-11-05       Impact factor: 5.157

5.  An integrated structure- and pharmacophore-based MMP-12 virtual screening.

Authors:  Mohammad Ramezani; Jamal Shamsara
Journal:  Mol Divers       Date:  2018-02-08       Impact factor: 2.943

6.  Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.

Authors:  Laurent Devel; Sandra Garcia; Bertrand Czarny; Fabrice Beau; Evelyne LaJeunesse; Laura Vera; Dimitris Georgiadis; Enrico Stura; Vincent Dive
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

Review 7.  Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects.

Authors:  Chen Zhang; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2009-03-31       Impact factor: 5.118

8.  Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling.

Authors:  Baohong Jiang; Jing Chen; Lingling Xu; Zhenting Gao; Yanping Deng; Yanhui Wang; Feng Xu; Xu Shen; De-An Guo
Journal:  BMC Pharmacol       Date:  2010-08-25

9.  Ligand-induced changes in the structure and dynamics of Escherichia coli peptide deformylase.

Authors:  Carlos D Amero; Douglas W Byerly; Craig A McElroy; Amber Simmons; Mark P Foster
Journal:  Biochemistry       Date:  2009-08-18       Impact factor: 3.162

Review 10.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.